Your browser doesn't support javascript.
loading
HER2 activating mutations are targets for colorectal cancer treatment.
Kavuri, Shyam M; Jain, Naveen; Galimi, Francesco; Cottino, Francesca; Leto, Simonetta M; Migliardi, Giorgia; Searleman, Adam C; Shen, Wei; Monsey, John; Trusolino, Livio; Jacobs, Samuel A; Bertotti, Andrea; Bose, Ron.
Afiliação
  • Kavuri SM; Division of Oncology, Department of Medicine, Washington University School of Medicine, St. Louis, Missouri.
  • Jain N; Division of Oncology, Department of Medicine, Washington University School of Medicine, St. Louis, Missouri.
  • Galimi F; Department of Oncology, University of Torino Medical School, Torino, Italy. Translational Cancer Medicine, Candiolo Cancer Institute - FPO IRCCS, Torino, Italy.
  • Cottino F; Translational Cancer Medicine, Candiolo Cancer Institute - FPO IRCCS, Torino, Italy.
  • Leto SM; Department of Oncology, University of Torino Medical School, Torino, Italy. Translational Cancer Medicine, Candiolo Cancer Institute - FPO IRCCS, Torino, Italy.
  • Migliardi G; Department of Oncology, University of Torino Medical School, Torino, Italy. Translational Cancer Medicine, Candiolo Cancer Institute - FPO IRCCS, Torino, Italy.
  • Searleman AC; Division of Oncology, Department of Medicine, Washington University School of Medicine, St. Louis, Missouri.
  • Shen W; Division of Oncology, Department of Medicine, Washington University School of Medicine, St. Louis, Missouri.
  • Monsey J; Division of Oncology, Department of Medicine, Washington University School of Medicine, St. Louis, Missouri.
  • Trusolino L; Department of Oncology, University of Torino Medical School, Torino, Italy. Translational Cancer Medicine, Candiolo Cancer Institute - FPO IRCCS, Torino, Italy.
  • Jacobs SA; NSABP Foundation, Pittsburgh, Pennsylvania.
  • Bertotti A; Department of Oncology, University of Torino Medical School, Torino, Italy. Translational Cancer Medicine, Candiolo Cancer Institute - FPO IRCCS, Torino, Italy. National Institute of Biostructures and Biosystems, Rome, Italy. rbose@dom.wustl.edu andrea.bertotti@ircc.it.
  • Bose R; Division of Oncology, Department of Medicine, Washington University School of Medicine, St. Louis, Missouri. Alvin J. Siteman Cancer Center, Washington University School of Medicine, St. Louis, Missouri. rbose@dom.wustl.edu andrea.bertotti@ircc.it.
Cancer Discov ; 5(8): 832-41, 2015 Aug.
Article em En | MEDLINE | ID: mdl-26243863
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias Colorretais / Receptor ErbB-2 / Mutação Tipo de estudo: Diagnostic_studies / Prognostic_studies Limite: Animals / Humans Idioma: En Ano de publicação: 2015 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias Colorretais / Receptor ErbB-2 / Mutação Tipo de estudo: Diagnostic_studies / Prognostic_studies Limite: Animals / Humans Idioma: En Ano de publicação: 2015 Tipo de documento: Article